AzTrials
AzTrials

Atrial FibrillationNCT06475547

Inflammation and Postoperative Atrial Fibrillation in Cardiac Surgery

An observational study of Atrial Fibrillation and Inflammation, run by Odense University Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, marked by an irregular and rapid heart rate, and associated with increased morbidity, longer hospital stays, and higher costs. Its complex pathophysiology involves atrial remodeling, inflammation, and autonomic dysregulation. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Atrial Fibrillation, Inflammation
What is being tested?
Descriptive
How many people
85 participants
Where
1 siteDenmark
Study dates
1 Jan 2022to 1 Jan 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients undergoing cardiac surgery

Who may be able to join

  • Age > 18
  • Informed consent

Who cannot join

  • Incompetent individuals
  • General poor health condition at the time of inclusion
  • Reoperation

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Odense University Hospital, Cardiac Surgery Department

    Odense, 5000

Other trials in Denmark

About this study

Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, marked by an irregular and rapid heart rate, and associated with increased morbidity, longer hospital stays, and higher costs. Its complex pathophysiology involves atrial remodeling, inflammation, and autonomic dysregulation. Surgical trauma and cardiopulmonary bypass trigger an inflammatory response, releasing cytokines. Epicardial fat around the heart secretes pro-inflammatory cytokines, and its increased thickness is linked to higher inflammation and atrial fibrillation. This study uses RNA sequencing (RNA-seq) to profile gene expression in epicardial fat, identifying key genes involved in inflammation and metabolism. By comparing patients with and without POAF, RNA-seq reveals differentially expressed genes associated with postoperative atrial fibrillation.

Read the detailed description

Postoperative Atrial Fibrillation (POAF) after Cardiac Surgery Postoperative atrial fibrillation is a common complication following cardiac surgery, characterized by irregular and often rapid heart rate. It is associated with increased morbidity, prolonged hospital stays, and higher healthcare costs. The pathophysiology of POAF is complex and multifactorial, involving atrial structural and electrical remodeling, inflammation, and autonomic dysregulation.

Inflammation and Epicardial Fat Inflammation plays a significant role in the development of POAF. Surgical trauma and cardiopulmonary bypass trigger a systemic inflammatory response, releasing cytokines and other inflammatory mediators. Epicardial fat, the visceral fat depot around the heart, is an active endocrine organ secreting pro-inflammatory cytokines and adipokines. Increased epicardial fat thickness is associated with higher levels of inflammation and has been implicated in the pathogenesis of atrial fibrillation.

RNA isolation and sequencing RNA sequencing (RNA-seq) can be used to investigate gene expression in epicardial fat in several impactful ways. RNA-seq can profile gene expression to identify active genes in epicardial fat and their expression levels, revealing key genes involved in inflammation and metabolism. By comparing gene expression between groups, such as patients with and without POAF, RNA-seq can identify differentially expressed genes associated with atrial fibrillation.

RNA-seq analyses The RNA sequencing data files were aligned to the hg38 reference genome using the Spliced Transcripts Alignment to a Reference (STAR) aligner and read counts in genes were quantified. The resulting data matrix with unnormalized counts was loaded into RStudio together with patient metadata information (e.g., age, gender, BMI, smoking). Differential expression analyses were conducted with DESeq2 using adjustment for different variables, including type of tissue, age of patients, gender, and BMI.

Hypothesis The hypothesis that POAF may be influenced by pre-existing inflammation in epicardial fat, in addition to the inflammation caused by surgical trauma.

Objective:

To compare inflammatory gene expression in epicardial fat between patients who develop POAF and those who do not after elective cardiac surgery.

Study Design:

A prospective cohort study including patients undergoing first-time elective cardiac surgery.

Participants:

Inclusion criteria: Patients undergoing first-time elective cardiac surgery. Exclusion criteria: Patients with previous cardiac surgeries or emergency surgeries.

Groups:

POAF Group: Patients who develop POAF. Non-POAF Group: Patients who do not develop POAF.

Sample Collection:

Epicardial fat samples will be collected during the time of surgery.

RNA Isolation and Sequencing:

Homogenize adipose tissue in TRIzol using ceramic beads (Fastprep 24, MPBio). Purify RNA using EconoSpin columns (Epoch). Prepare RNA libraries with NEBNext Ultra II RNA Library Prep Kit for Illumina. Perform paired-end sequencing on the NovaSeq 6000 platform (Illumina).

Data Analysis:

Align RNA-seq data to the hg38 genome using STAR aligner. Quantify gene counts and perform differential expression analysis using DESeq2. Adjust for variables such as tissue type, age, gender, and BMI.

Outcome Measures:

Compare inflammatory gene expression profiles between POAF and Non-POAF groups at the time of surgery.

Being tested
Descriptive
Medical subject headings
Atrial Fibrillation, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DescriptiveOther

    This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.

Study groups in NCT06475547
Study groupRoleWhat they receive
POAFPatients who develop postoperative atrial fibrillation.
Receives: Other: Descriptive
Non-POAFPatients who do not develop postoperative atrial fibrillation.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Differential expression of genes

    The primary endpoint of this study is to identify differentially expressed (DE) genes using RNA sequencing (RNA-seq) data. Post-sequencing, we will utilize the default settings and statistical methods provided by DESeq2 to determining statistically significant differences in gene expression between the experimental conditions.

    The gene signal is measured in normalized counts per kilobase or in Fragments Per Kilobase of transcript per Million mapped reads.

    Measured: The sample is taken at the time of surgery.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2024
  2. Study start1 Jan 2022
  3. Primary completion1 Jan 2026
  4. Study completion1 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
85 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06475547
Sponsor's protocol ID
POAF130624
Status last verified
Oct 2026
First submitted
20 Jun 2024
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be available in anonymized form in accordance with GDPR upon reasonable request. Data will be shared with researchers whose proposed use has been approved, primarily for replication of our results.

Publications

  • Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013 Jan 1;29(1):15-21. doi: 10.1093/bioinformatics/bts635. Epub 2012 Oct 25.

    PubMed 23104886
  • Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8.

    PubMed 25516281
  • Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017 May 1;38(17):1294-1302. doi: 10.1093/eurheartj/ehw045.

    PubMed 26935271

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation and Inflammation, run by Odense University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Differential expression of genes (time frame: The sample is taken at the time of surgery.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06475547, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in